Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Trends in antimicrobial resistance over 10 years among key bacterial pathogens from Canadian hospitals: results of the CANWARD study 2007-16.

Lagacé-Wiens PRS, Adam HJ, Poutanen S, Baxter MR, Denisuik AJ, Golden AR, Nichol KA, Walkty A, Karlowsky JA, Mulvey MR, Golding G, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv22-iv31. doi: 10.1093/jac/dkz284.

PMID:
31505648
2.

Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016.

Denisuik AJ, Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PRS, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv64-iv71. doi: 10.1093/jac/dkz289.

PMID:
31505647
3.

Characterization of MRSA in Canada from 2007 to 2016.

Nichol KA, Adam HJ, Golding GR, Lagacé-Wiens PRS, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv55-iv63. doi: 10.1093/jac/dkz288.

PMID:
31505646
4.

Comparison of antimicrobial resistance patterns in Streptococcus pneumoniae from respiratory and blood cultures in Canadian hospitals from 2007-16.

Golden AR, Baxter MR, Davidson RJ, Martin I, Demczuk W, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG, Adam HJ; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv39-iv47. doi: 10.1093/jac/dkz286.

PMID:
31505644
5.

Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.

McCracken MG, Adam HJ, Blondeau JM, Walkty AJ, Karlowsky JA, Hoban DJ, Zhanel GG, Mulvey MR; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv32-iv38. doi: 10.1093/jac/dkz285.

PMID:
31505643
6.

42936 pathogens from Canadian hospitals: 10 years of results (2007-16) from the CANWARD surveillance study.

Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Golden AR, Hink R, Lagacé-Wiens PRS, Walkty A, Mulvey MR, Schweizer F, Bay D, Hoban DJ, Karlowsky JA; Canadian Antimicrobial Resistance Alliance (CARA) and CANWARD .

J Antimicrob Chemother. 2019 Aug 1;74(Supplement_4):iv5-iv21. doi: 10.1093/jac/dkz283.

PMID:
31505641
7.

Activity of Ceftolozane-Tazobactam and Comparators against Pseudomonas aeruginosa from Patients in Different Risk Strata -- SMART United States 2016-2017.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2019 Jul 24. pii: S2213-7165(19)30183-3. doi: 10.1016/j.jgar.2019.07.017. [Epub ahead of print]

PMID:
31351246
8.

Antimicrobial-resistant pathogens in Canadian ICUs: results of the CANWARD 2007 to 2016 study.

Denisuik AJ, Garbutt LA, Golden AR, Adam HJ, Baxter M, Nichol KA, Lagacé-Wiens P, Walkty AJ, Karlowsky JA, Hoban DJ, Mulvey MR, Zhanel GG.

J Antimicrob Chemother. 2019 Mar 1;74(3):645-653. doi: 10.1093/jac/dky477.

PMID:
30500898
9.

Molecular characterization of predominant Streptococcus pneumoniae serotypes causing invasive infections in Canada: the SAVE study, 2011-15.

Golden AR, Adam HJ, Karlowsky JA, Baxter M, Nichol KA, Martin I, Demczuk W, Van Caeseele P, Gubbay JB, Lefebvre B, Levett PN, Zahariadis G, Haldane D, Gad R, German G, Gilmour MW, Mulvey MR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii20-vii31. doi: 10.1093/jac/dky157.

PMID:
29982573
10.

Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the SAVE study, 2011-15.

Adam HJ, Golden AR, Karlowsky JA, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii12-vii19. doi: 10.1093/jac/dky158.

PMID:
29982572
11.

Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-15.

Karlowsky JA, Adam HJ, Golden AR, Baxter MR, Nichol KA, Martin I, Demczuk W, Mulvey MR, Gilmour MW, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance (CARA).

J Antimicrob Chemother. 2018 Jul 1;73(suppl_7):vii5-vii11. doi: 10.1093/jac/dky156.

PMID:
29982570
12.

Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:12-19. doi: 10.1016/j.jgar.2018.05.017. Epub 2018 May 29.

PMID:
29857057
13.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
14.

Correction to: Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 May;78(7):787. doi: 10.1007/s40265-018-0910-x.

PMID:
29748749
15.

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16.

Walkty A, Adam H, Baxter M, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2018 Mar 1;73(3):703-708. doi: 10.1093/jac/dkx468.

PMID:
29244121
16.

Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:.

PMID:
29230684
17.

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

Lagacé-Wiens PRS, Adam HJ, Laing NM, Baxter MR, Martin I, Mulvey MR, Karlowsky JA, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2017 Aug 1;72(8):2273-2277. doi: 10.1093/jac/dkx147.

PMID:
28505331
18.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

Braz J Infect Dis. 2017 May - Jun;21(3):343-348. doi: 10.1016/j.bjid.2017.03.006. Epub 2017 Apr 8.

19.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
20.

Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

J Med Microbiol. 2017 Jan;66(1):61-69. doi: 10.1099/jmm.0.000421. Epub 2017 Feb 22.

PMID:
28051952
21.

Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2016 Dec;76(18):1737-1757. Review.

PMID:
27909995
22.

Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014.

Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Aug;85(4):459-65. doi: 10.1016/j.diagmicrobio.2016.04.022. Epub 2016 May 6.

PMID:
27306116
23.

Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.

Hackel M, Kazmierczak KM, Hoban DJ, Biedenbach DJ, Bouchillon SK, de Jonge BL, Stone GG.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4677-83. doi: 10.1128/AAC.02841-15. Print 2016 Aug.

24.

Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii.

Lob SH, Hoban DJ, Sahm DF, Badal RE.

Int J Antimicrob Agents. 2016 Apr;47(4):317-23. doi: 10.1016/j.ijantimicag.2016.01.015. Epub 2016 Mar 5.

PMID:
27020541
25.

Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.

Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty A, Gin AS, Hoban DJ, Karlowsky JA.

Drugs. 2016 Apr;76(5):567-88. doi: 10.1007/s40265-016-0545-8. Review.

PMID:
26863149
26.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Alm RA, Lahiri SD, Reiszner E, Hoban DJ, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):343-7. doi: 10.1128/AAC.01867-15. Print 2016 Jan.

27.

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Biedenbach DJ, Hoban DJ, Reiszner E, Lahiri SD, Alm RA, Sahm DF, Bouchillon SK, Ambler JE.

Antimicrob Agents Chemother. 2015 Dec;59(12):7873-7. doi: 10.1128/AAC.01833-15. Epub 2015 Sep 28.

28.

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.

Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ.

Ann Clin Microbiol Antimicrob. 2015 May 10;14:27. doi: 10.1186/s12941-015-0085-1.

29.

Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends.

Kazmierczak KM, Lob SH, Hoban DJ, Hackel MA, Badal RE, Bouchillon SK.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):209-14. doi: 10.1016/j.diagmicrobio.2015.03.025. Epub 2015 Apr 9.

PMID:
25956930
30.

Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13.

Golden AR, Rosenthal M, Fultz B, Nichol KA, Adam HJ, Gilmour MW, Baxter MR, Hoban DJ, Karlowsky JA, Zhanel GG.

J Antimicrob Chemother. 2015 Aug;70(8):2199-202. doi: 10.1093/jac/dkv107. Epub 2015 Apr 28.

PMID:
25921512
31.

Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).

Simner PJ, Adam H, Baxter M, McCracken M, Golding G, Karlowsky JA, Nichol K, Lagacé-Wiens P, Gilmour MW; Canadian Antimicrobial Resistance Alliance (CARA), Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2015 Jul;59(7):4315-7. doi: 10.1128/AAC.00384-15. Epub 2015 Apr 20.

32.

Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010-2012.

Hackel MA, Badal RE, Bouchillon SK, Biedenbach DJ, Hoban DJ.

Surg Infect (Larchmt). 2015 Jun;16(3):298-304. doi: 10.1089/sur.2014.060. Epub 2015 Apr 20.

PMID:
25894976
33.

Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13.

Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, Demczuk WH, Hoban DJ, Zhanel GG.

J Antimicrob Chemother. 2015 Jul;70(7):1960-4. doi: 10.1093/jac/dkv061. Epub 2015 Mar 11.

PMID:
25761605
34.

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Zhanel GG, Love R, Adam H, Golden A, Zelenitsky S, Schweizer F, Gorityala B, Lagacé-Wiens PR, Rubinstein E, Walkty A, Gin AS, Gilmour M, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7. Review.

PMID:
25673021
35.

Global incidence of carbapenemase-producing Escherichia coli ST131.

Peirano G, Bradford PA, Kazmierczak KM, Badal RE, Hackel M, Hoban DJ, Pitout JD.

Emerg Infect Dis. 2014 Nov;20(11):1928-31. doi: 10.3201/eid2011.141388.

36.

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012.

Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P.

J Glob Antimicrob Resist. 2014 Sep;2(3):179-182. doi: 10.1016/j.jgar.2014.03.002. Epub 2014 Mar 26.

PMID:
27873726
37.

Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011).

Biedenbach DJ, Bouchillon SK, Hoban DJ, Hackel M, Phuong DM, Nga TT, Phuong NT, Phuong TT, Badal RE.

Diagn Microbiol Infect Dis. 2014 Aug;79(4):463-7. doi: 10.1016/j.diagmicrobio.2014.05.009. Epub 2014 May 17.

PMID:
24923210
38.

Susceptibility of Staphylococcus aureus to topical agents in the United States: a sentinel study.

Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M.

Clin Ther. 2014 Jun 1;36(6):953-60. doi: 10.1016/j.clinthera.2014.04.003. Epub 2014 May 15.

PMID:
24835558
39.

Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.

Zhanel GG, Denisuik A, Vashisht S, Yachison C, Adam HJ, Hoban DJ.

J Antimicrob Chemother. 2014 Sep;69(9):2448-52. doi: 10.1093/jac/dku149. Epub 2014 May 14.

PMID:
24827891
40.

In vitro susceptibility and distribution of beta-lactamases in Enterobacteriaceae causing intra-abdominal infections in North America 2010-2011.

Hoban DJ, Badal R, Bouchillon S, Hackel M, Kazmierczak K, Lascols C, Hawser S.

Diagn Microbiol Infect Dis. 2014 Jul;79(3):367-72. doi: 10.1016/j.diagmicrobio.2014.03.026. Epub 2014 Apr 12.

PMID:
24813688
41.

In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.

Renteria MI, Biedenbach DJ, Bouchillon SK, Hoban DJ, Raghubir N, Sajben P, Mokaddas E.

Diagn Microbiol Infect Dis. 2014 May;79(1):54-9. doi: 10.1016/j.diagmicrobio.2014.01.017. Epub 2014 Jan 30.

PMID:
24582580
42.

In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Walkty A, Adam H, Baxter M, Denisuik A, Lagacé-Wiens P, Karlowsky JA, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014 May;58(5):2554-63. doi: 10.1128/AAC.02744-13. Epub 2014 Feb 18.

43.

Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011.

Hawser S, Hoban DJ, Badal RE, Bouchillon SK, Biedenbach D, Hackel M, Morrissey I.

J Chemother. 2015 Feb;27(2):67-73. doi: 10.1179/1973947814Y.0000000164. Epub 2014 Feb 18.

PMID:
24548089
44.

Molecular epidemiology of Enterobacteriaceae that produce VIMs and IMPs from the SMART surveillance program.

Peirano G, Lascols C, Hackel M, Hoban DJ, Pitout JD.

Diagn Microbiol Infect Dis. 2014 Mar;78(3):277-81. doi: 10.1016/j.diagmicrobio.2013.11.024. Epub 2013 Dec 6.

PMID:
24387958
45.

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA.

Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Review.

PMID:
24352909
46.

In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.

Karlowsky JA, Denisuik AJ, Lagacé-Wiens PR, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2014;58(2):1252-6. doi: 10.1128/AAC.02399-13. Epub 2013 Dec 9.

47.

Susceptibility of gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011.

Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA.

J Infect. 2014 Jan;68(1):71-6. doi: 10.1016/j.jinf.2013.09.001. Epub 2013 Sep 7.

PMID:
24016768
48.

Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals.

Baudry-Simner PJ, Singh A, Karlowsky JA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

Can J Infect Dis Med Microbiol. 2012 Fall;23(3):e60-4.

49.

In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Karlowsky JA, Adam HJ, Baxter MR, Lagacé-Wiens PR, Walkty AJ, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2013 Nov;57(11):5600-11. doi: 10.1128/AAC.01485-13. Epub 2013 Aug 26.

50.

Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008.

Wierzbowski AK, Karlowsky JA, Adam HJ, Nichol KA, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance.

J Antimicrob Chemother. 2014 Jan;69(1):59-66. doi: 10.1093/jac/dkt332. Epub 2013 Aug 22.

PMID:
23970485

Supplemental Content

Loading ...
Support Center